ArticleJournal of gynecologic oncology2024
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.
Gengwei Huo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this paperpooled itcites it